Atypical haemolytic uraemic syndrome (aHUS) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051103
Expand allThis document outlines details of PBS-subsidised eculizumab and ravulizumab for patients with atypical haemolytic uraemic syndrome (aHUS).
aHUS and listing dates
aHUS is a rare and life-threatening immune condition that causes abnormal blood clots to form in small blood vessels in the kidneys.
Listing dates:
- eculizumab - 1 December 2014
- ravulizumab - 1 January 2024
See Written Authority Required Drugs for more details.
Enquiries
Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs and choose the option relevant to the condition treated.
The Resources page contains:
- application forms
- calculation sheets
- contact details
- restriction and item codes
- the PBS schedule
- Services Australia website link
Related links
Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)
Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)
Processing and National Demand Allocation (PaNDA)
Processing Complex Authority Required Listings
Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)
Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)
Written Authority Required Drugs